Correspondence 0001193125-23-201389 from Telesis Bio Inc. (TBIO) (CIK 0001850079)
Telesis Bio Inc. (TBIO) (CIK 0001850079)
Date: Aug. 2, 2023 · CIK: 0001850079 · Accession: 0001193125-23-201389
AI Filing Summary & Sentiment
File numbers found in text: 333-273491
Letter
August 2, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549-3720
Attention: Jessica Ansart
Re: Telesis Bio Inc.
Registration Statement on Form S-3
Filed July 27, 2023
File No. 333-273491
Acceleration Request
Requested Date: August 3, 2023
Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Telesis Bio Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-273491) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Jesse Schumaker at (303) 256-5909.
In connection with the acceleration request, the Company hereby acknowledges that:
•
should the Commission or the Staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
•
the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
•
the Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
* * * *
Sincerely,
TELESIS BIO INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP August 2, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Jessica Ansart Re: Telesis Bio Inc. Registration Statement on Form S-3 Filed July 27, 2023 File No. 333-273491 Acceleration Request Requested Date: August 3, 2023 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Telesis Bio Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-273491) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Jesse Schumaker at (303) 256-5909. In connection with the acceleration request, the Company hereby acknowledges that: • should the Commission or the Staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement; • the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and • the Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. * * * * Sincerely, TELESIS BIO INC. By: /s/ Robert Cutler Robert Cutler Chief Legal Officer cc: Philip Oettinger, Wilson Sonsini Goodrich & Rosati, P.C. Jesse Schumaker, Wilson Sonsini Goodrich & Rosati, P.C. Todd Nelson, Chief Executive Officer, Telesis Bio Inc.